Announcement of Extraordinary Gains(Gain on Sale of Investment Securities)
FY2023 Third Quarter Financial Results Presentation Summary of Q&A Session
Announcement of Discontinuation of Development of a Norovirus Vaccine in an Overseas Consolidated Subsidiary and Recording of Extraordinary Loss
FY2023 Third Quarter Financial Results Presentation Materials
Notice Regarding Changes in Executive Officers
FY2023 Third Quarter Summary of Consolidated Financial Statements
This website uses cookies to ensure that you use this website comfortably. If you continue to browse this website, you will agree to the use of our cookies.